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Abstract
Forward genetic screens are powerful tools for the discovery and functional annotation of genetic 
elements. Recently, the RNA-guided CRISPR (clustered regularly interspaced short palindromic 
repeat)-associated Cas9 nuclease has been combined with genome-scale guide RNA libraries for 
unbiased, phenotypic screening. In this Review, we describe recent advances using Cas9 for 
genome-scale screens, including knockout approaches that inactivate genomic loci and strategies 
that modulate transcriptional activity. We discuss practical aspects of screen design, provide 
comparisons with RNA interference (RNAi) screening, and outline future applications and 
challenges.
A key goal in genetic analysis is to identify which genes contribute to specific biological 
phenotypes and diseases. Hypothesis-driven, reverse genetic methods take a ‘genotype-to-
phenotype’ approach by using prior knowledge to test the causal role of specific genetic 
perturbations. By contrast, forward genetic screens are ‘phenotype-to-genotype’ approaches 
that involve modifying or modulating the expression of many genes, selecting for the cells 
or organisms with a phenotype of interest, and then characterizing the mutations that result 
in those phenotypic changes.
Initial forward genetic experiments carried out on model organisms such as yeast, flies, 
plants, zebrafish, nematodes and rodents1–9 relied on the use of chemical DNA mutagens 
followed by the isolation of individuals with an aberrant phenotype. These screens have 
uncovered many basic biological mechanisms, such as RAS and NOTCH signalling 
pathways10, as well as molecular mechanisms of embryonic patterning11,12 and 
development13,14.
A major shortcoming of DNA-mutagen-based screens is that the causal mutations in the 
selected clones are initially unknown. Identifying the causal mutations can be costly and 
labour intensive, requiring linkage analysis through crosses with characterized lines. These 
challenges can now be more easily addressed by mapping mutations using next-generation 
sequencing (NGS)15 and by replacing chemical mutagens with viruses and transposons, 
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which use defined insertion sequences that are amenable to sequencing-based analysis16–18. 
An additional limitation of random mutagenesis approaches is that the resulting mutants are 
typically heterozygotes, which can mask recessive phenotypes. In model organisms, 
homozygosity can be achieved by intercrossing progeny derived from the initial 
heterozygous mutant. In mammalian cell culture, recessive screens have been limited to 
near-haploid cell lines19,20 or to cell lines that are deficient in Bloom helicase (BLM), which 
have an increased rate of mitotic recombination21.
Over the past decade, forward genetic screens have been revolutionized by the development 
of tools that use the RNA interference (RNAi) pathway for gene knockdown. RNAi is a 
conserved endogenous pathway in which mRNA molecules are targeted for degradation on 
the basis of sequence complementarity22,23, thus facilitating design and scalability of the 
tools. Several RNAi reagents have been developed, including long double-stranded RNA 
(dsRNA)24, synthetic small interfering RNA (siRNA)25, short hairpin RNA (shRNA)26 and 
shRNAs embedded in microRNA (miRNA) precursors (shRNAmirs)27,28. Screens using 
RNAi tools have provided a wealth of information on gene function1,26,29–32, but their 
utility has been hindered by incomplete gene knockdown and extensive off-target activity, 
making it difficult to interpret phenotypic changes33–35.
Sequence-specific programmable nucleases have emerged as an exciting new genetic 
perturbation system that enables the targeted modification of the DNA sequence itself. In 
particular, the RNA-guided endo-nuclease Cas9 (REFS 36–41) from the microbial adaptive 
immune system CRISPR (clustered regularly interspaced short palindromic repeat) provides 
a convenient system for achieving targeted mutagenesis in eukaryotic cells42,43. Cas9 is 
targeted to specific genomic loci via a guide RNA, which recognizes the target DNA 
through Watson–Crick base pairing. Therefore, Cas9 combines the permanently mutagenic 
nature of classical mutagens with the programmability of RNAi.
In this Review, we discuss recent Cas9-based functional genetic screening tools, including 
genome-wide knockout approaches and related strategies using modified forms of Cas9 to 
cause gene knockdown or transcriptional activation in a non-mutagenic manner44–49. We 
discuss how these newer approaches compare with and complement existing RNAi-based 
screening technologies. We also present some practical considerations for designing Cas9-
based screens and potential future directions for targeted screening technology development.
Mechanisms of perturbation
Loss-of-function perturbations mediated by Cas9 and RNAi
Cas9 nuclease is a component of the type II CRISPR bacterial adaptive immune system that 
has recently been adapted for genome editing in many eukaryotic models (reviewed in REFS 
50,51). Targeted genome engineering with Cas9 and other nucleases exploits endogenous 
DNA double-strand break (DSB) repair pathways to create mutations at specific locations in 
the genome. Although there is a large diversity of DSB repair mechanisms, genome editing 
in mammalian cells primarily relies on homology-directed repair (HDR), in which an 
exogenous DNA template can facilitate precise repair, as well as non-homologous end-
joining (NHEJ), which is an error-prone repair mechanism that introduces indel mutations at 
Shalem et al. Page 2
Nat Rev Genet. Author manuscript; available in PMC 2015 November 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
the repair site52. To induce DSBs, Cas9 can be targeted to specific locations in the genome 
by specifying a short single guide RNA (sgRNA)41 to complement the target DNA. For the 
commonly used Streptococcus pyogenes Cas9, the sgRNA contains a 20-bp guide sequence. 
The target DNA needs to contain the 20-bp target sequence followed by a 3-bp protospacer-
adjacent motif (PAM), although some mismatches can be tolerated (see below).
Loss-of-function mutations mediated by Cas9 nuclease are achieved by targeting a DSB to a 
constitutively spliced coding exon. When a DSB is repaired by NHEJ, it can introduce an 
indel mutation. This frequently causes a coding frameshift, resulting in a premature stop 
codon and the initiation of nonsense-mediated decay (NMD) of the transcript (FIG. 1). 
NMD might not be active for all genes and is not necessarily required for Cas9-mediated 
knockout, as an early frameshift mutation or large indels might be sufficient to produce a 
non-functional protein. Early exons are preferred for targeting, as indels in these exons have 
a higher probability of introducing an early stop codon or a frameshift of a larger portion of 
the protein53. As DSB induction and NHEJ-mediated repair occur independently at each 
allele in diploid cells, targeting by Cas9 results in a range of biallelic and heterozygous 
target gene lesions in different cells. We and others44–47 have used the simple, RNA-
mediated programmability of Cas9 and its nuclease function to conduct genome-scale 
knockout screens in mammalian cell cultures. These initial screens uncovered both known 
and novel insights into gene essentiality and resistance to drugs and toxins. Most 
importantly, Cas9-based screens displayed high reagent consistency, strong phenotypic 
effects and high validation rates, demonstrating the promise of this approach.
Although the application of Cas9 to targeted screening is relatively recent, similar 
approaches based on RNAi technologies have been extensively used over the past decade in 
mammalian cell culture and in vivo1,3,26,29,30,54–58. RNAi is a conserved natural pathway 
that is triggered by various types of dsRNAs (often single-stranded RNAs folded into 
hairpin structures) and that results in the selective downregulation of transcripts with 
sequence complementarity to one strand of the dsRNA23. Natural sources of dsRNAs 
include endogenous mi RNAs59 and exogenous linear dsRNAs that are typically introduced 
into cells by invading viruses60–62. Artificial targeted gene knockdown is achieved by the 
delivery of a wide range of designed RNAi reagents55,63, including long dsRNAs24, 
siRNAs25, shRNAs26 and miRNA-embedded shRNAs27,28. The delivery of RNAi reagents 
is achieved by transfection of pre-synthesized RNA (for siRNAs and dsRNAs), by 
transfection of DNA (which encodes a promoter-driven shRNA or shRNAmir) or by viral 
transduction methods using lentiviral, retroviral or transposon constructs with a cloned 
shRNA or shRNAmir cassette (FIG. 1). In contrast to RNA polymerase III (Pol III)-driven 
expression of shRNAs or sgRNAs, Pol II-driven expression of shRNAmirs can be 
temporally controlled and genetically restricted across tissues63. Most RNAi reagents are 
nucleolytically processed by the enzyme Dicer into functional siRNAs. Before processing 
by Dicer, shRNAmirs require nuclear processing by Drosha–DGCR8, but this step is usually 
bypassed with other reagents63. Regardless of the reagent type, the resultant siRNAs are 
then loaded into the RNA-induced silencing complex (RISC), which is guided to the target 
mRNA molecule by the siRNA to initiate mRNA degradation or translational inhibition23.
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Catalytically inactive Cas9 for transcriptional modulation
In addition to gene knockout that is mediated by the error-prone repair of targeted DSBs and 
RNAi-based gene knockdowns, catalytically inactive Cas9 (dCas9) and various fusions of 
either dCas9 or sgRNAs with transcriptional activator, repressor and recruitment domains 
have been used to modulate gene expression at targeted loci without introducing irreversible 
mutations to the genome. The dCas9-based transcriptional inhibition and activation systems 
are commonly referred to as CRISPRi and CRISPRa, respectively (FIG. 2). dCas9 by itself 
can have a repressive effect on gene expression, which is probably due to steric hindrance of 
the components of the transcription initiation and elongation machinery64,65 (FIG. 2Aa). 
Although this approach has been successful in Escherichia coli, the degree of repression 
achieved in mammalian cells has been modest64–68. Chromatin-modifying repressor 
domains have been fused to dCas9 in an attempt to improve repression in mammalian cells66 
(FIG. 2Ab). However, the magnitude of repression displayed high variability across sgRNAs 
even with these fusion proteins66. To achieve a more robust effect, sgRNA libraries tiling 
the upstream regions of genes were constructed, and the variability in the measured effect on 
transcription was used to infer rules for the design of more-potent repressive sgRNAs48. 
These rules included the sgRNA target location relative to the transcription start site, the 
length of the protospacer and the spacer nucleotide composition features48. Although dCas9-
mediated repression and RNAi-based tools seem to result in a similar molecular effect, 
dCas9 repression occurs by inhibiting transcription, whereas RNAi acts on the mRNAs in 
the cytoplasm. These differences might result in varying cellular responses.
Whereas loss-of-function screens can be conducted using a variety of both established and 
new Cas9-based tools, gain-of-function screens have been limited to cDNA overexpression 
libraries69. The coverage of such libraries is incomplete owing to the difficulty of cloning or 
expressing large cDNA constructs. Furthermore, these libraries often do not capture the full 
complexity of transcript isoforms, and they express genes independently of the endogenous 
regulatory context. To facilitate Cas9-based gain-of-function screens, synthetic activators 
were constructed by fusing dCas9 with transcriptional activation domains such as VP64 or 
p65 (REFS 68,70–73) (FIG. 2Ba). However, these fusions only led to modest activation 
when delivered with a single sgRNA in mammalian cells. The delivery of multiple sgRNAs 
targeting the same promoter region improved target gene activation70–72, but this was still 
not reliable enough to implement genome-wide activation screens. To amplify the signal of 
dCas9 fusion effector domains, a repeating peptide array of epitopes fused to dCas9 was 
developed together with activation effector domains fused to a single-chain variable 
fragment (ScFv) antibody74 (FIG. 2Bb). Similar to the repression screen, a tiling approach 
was then used to infer rules for potent sgRNAs, followed by the design of a genome-wide 
library and the implementation of an activation screen48.
We recently took advantage of a crystal structure of Cas9 in complex with a guide RNA and 
target single-stranded DNA (ssDNA)75 to rationally design an efficient Cas9 activation 
complex composed of a dCas9 fusion protein and modified sgRNA49 (FIG. 2Bc). This 
design was guided by the following principles: the use of alternative attachment positions to 
recruit endogenous transcription machineries more effectively; the mimicking of natural 
transcriptional activation mechanisms by recruiting multiple distinct activators that act in 
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synergy to drive transcription; and the identification of design rules for efficient positioning 
of the Cas9 activation complex on the promoter. We used this design to implement a 
genome-wide gain-of-function screen49 to identify genes that confer vemurafenib resistance 
in melanoma cells when upregulated.
Modified scaffolds with different RNA-binding motifs were recently developed for both 
activation and repression of gene expression76 (FIG. 2C). A combination of these scaffolds 
enabled the execution of complex synthetic transcriptional programmes with the 
simultaneous activation and repression of different genes.
The most apparent advantage of dCas9-mediated transcriptional activation is that induction 
originates from the endogenous gene locus (unlike expression from an exogenous cDNA 
construct). Yet, the extent to which synthetic transcriptional modulators preserve the 
complexity of transcript isoforms and different types of feedback regulation remains to be 
tested77,78. In one tested case49, two transcript isoforms were expressed at equal levels, 
suggesting that transcript complexity can be preserved. One important advantage of cDNA 
expression vectors is the ability to easily express mutated genes without modifying the 
endogenous genomic loci.
Libraries and screening strategies
Functional screens in cultured cells are conducted in two general formats: arrayed or pooled 
(FIG. 3). In an arrayed format, individual reagents are arranged in multiwell plates with a 
single reagent (or a small pool of reagents) per well. As each reagent is separately prepared, 
arrayed resources are more expensive and time consuming to produce than reagents for 
pooled screening, and conducting arrayed screens can require special facilities that use 
automation for the handling of many plates. However, in arrayed screens, where each well 
has a single known genetic perturbation, a much wider range of cellular phenotypes can be 
investigated using fluorescence, luminescence and high-content imag analysis54,79–81 (FIG. 
3).
For arrayed screens, reagents can be delivered by either transfection or viral transduction. 
Using transfection, a large amount of plasmid DNA encoding the RNA reagent (or pre-
synthesized RNA reagent) is delivered into cells, resulting in transiently high levels of 
functional RNA reagents (sgRNAs, shRNAs or siRNAs) until the transfected reagents are 
diluted out through cell division and degradation. Using viral transduction, the multiplicity 
of infection (MOI) can be kept low such that most cells receive a single virus that is stably 
integrated. These distinct kinetics of reagent expression from transfection versus viral 
transduction approaches can result in differences in target specificity (discussed below).
Screening reagents in pooled formats are easier to produce owing to the availability of 
oligonucleotide library synthesis technologies82,83. In silico-designed libraries are 
synthesized as a highly complex pool of oligonucleotides. These oligonucleotides are then 
cloned as a pool to create a plasmid library that is used for virus production and screening26. 
Unlike the transfection and viral transduction options of arrayed screens, pooled screens are 
limited to low-MOI viral delivery. Stable transgene integration in pooled formats facilitates 
screen readout using NGS. This is carried out by preparing genomic DNA from the cell 
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population, sequencing across the sgRNA-encoding or shRNA-encoding regions of the viral 
integrants, and then mapping each sequencing read to a pre-compiled table of the designed 
sgRNA or shRNA library. This results in the quantification of the relative proportion of 
different integrated library constructs in the cell population.
Pooled screens are less expensive and labour intensive than arrayed screens. However, both 
approaches still require proficiency in molecular biology, tissue culture and data analysis. It 
is easier to carry out screens that require long culture times in pooled formats than in arrayed 
formats, as the latter often use small culture volumes (for example, 384-well plates) and 
require special robotic equipment for passaging many plates at once. In addition, pooled 
approaches enable screening in in vivo environments56–58,84–86. Conversely, pooled 
approaches are limited to growth phenotypes (that is, effects on cell proliferation or 
survival) or to cell-autonomous phenotypes that are selectable by cell sorting as fluorescence 
or cell surface markers.
Recent Cas9–sgRNA screens44–49 in mammalian cell culture used a pooled screening 
approach with libraries that ranged from 103 to 105 sgRNAs. All of these libraries contained 
sgRNA redundancy (multiple distinct sgRNAs that target the same gene) and targeted either 
human or mouse genomes (TABLE 1). They all used cell growth as a phenotype and 
showed both positive and negative selection results.
In positive selection screens, a strong selective pressure is introduced such that there is only 
a low probability that cells without a relevant survival-enhancing perturbation will remain 
following selection. Commonly, positive selection experiments are designed to identify 
perturbations that confer resistance to a drug, toxin or pathogen. One example is a screen for 
host genes that are essential for the intoxication of cells by anthrax toxin47. In this case, 
most sgRNAs are depleted owing to the strong selective pressure of the toxin, and only a 
small number of cells, which are transduced with sgRNAs that introduce a protective 
mutation, survive and proliferate. As very few hits are usually expected and resistant cells 
continue to proliferate, the signal is strong and easy to detect in pooled approaches.
In negative selection, the goal is to identify perturbations that cause cells to be depleted 
during selection; such perturbations typically affect genes that are necessary for survival 
under the chosen selective pressure. The simplest negative selection screen is continued 
growth for an extended period of time: in this case, the depleted cells are those carrying 
reagents that target genes that are essential for cell proliferation. These genes can be found 
by comparing the relative frequency of each sgRNA between a late time point and an earlier 
one. Negative selection screens almost always require greater sensitivity to changes in the 
representation of library reagents, as the depletion level is more modest and the number of 
depleted genes is larger (for example, essential genes). Moreover, when using Cas9 
nuclease, there is a chance that not all mutations will abolish gene function owing to small 
in-frame mutations, resulting in a mixed phenotype. One important application of negative 
selection screens is the identification of gene perturbations that selectively target cancer 
cells which harbour known oncogenic mutations; these ‘oncogene addictions’ might serve as 
possible drug targets87,88.
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Target specificity
Target specificity is an important point of consideration for all gene perturbation systems 
(TABLE 2). It consists of the ratio between on-target efficacy and unintended off-target 
effects, which is manifested by the consistency between unique reagents that target the same 
gene. On-target efficacy is a measure of how well a reagent can modify the expression of its 
intended gene target. Off-target effects include the perturbation of unintended genetic 
elements and global cellular responses. Target specificity will depend on the exact 
experimental settings. For example, as the concentrations of Cas9 and sgRNA affect target 
specificity89, transient transfections will differ from low-MOI transductions in target 
specificity.
Gene targeting reagent consistency
One of the encouraging results observed in the initial Cas9-mediated knockout screens44–47 
was that, for the top-scoring genes, a high percentage of unique sgRNAs designed to target 
the same genes were enriched following positive selection. One example is a screen carried 
out to identify gene knockouts that confer resistance to the chemotherapy etoposide45. As 
DNA topoisomerase 2A (TOP2A) creates cytotoxic DSBs during treatment with etoposide, 
TOP2A depletion results in drug resistance. Impressively, all ten distinct sgRNAs for the 
TOP2A gene showed high levels of enrichment in drug-treated samples. This level of 
consistency is rarely observed in RNAi-based screens, resulting in the generation of very 
large, high-coverage RNAi reagent libraries90. We have observed similar results44, in which 
a high percentage of sgRNAs for the top-scoring gene hits showed a strong phenotypic 
effect in a screen for resistance to the RAF inhibitor vemurafenib. We directly compared 
these results with a previous vemurafenib resistance screen using RNAi (shRNA)91. 
Interestingly, we found that the top ten hits of both screens (based on RIGER92 analysis) 
shared only a single gene and that reagent consistency was much higher for the hits in the 
Cas9 screen (78% versus 20% of reagents enriched). In another study that aimed to identify 
genes involved in susceptibility to 6-thioguanine (6-TG) and susceptibility to Clostridium 
septicum α-toxin in mouse embryonic stem cells46, both known and novel hits were found. 
Similarly, a higher percentage of sgRNAs were able to produce a phenotype than in shRNA 
knockdown when validated using individual sgRNAs for the top hits. In our positive 
selection vemurafenib screen, we also found a high validation rate with six of seven of the 
top hits reproducing the pooled screen results in arrayed-format drug titration curves44. 
Although these results are promising, more side-by-side comparisons with RNAi-based 
screens using different phenotypes and established RNAi screening platforms and 
libraries55,93 are needed. In addition, the main results to be emphasized by the recent Cas9-
knockout screens have been obtained using strong positive selection pressure. There is still a 
need for more-extensive validation and comparison to RNAi tools using negative selection 
experiments.
Despite the high consistency in strong positive selection screens, sgRNAs can still have 
large variations in efficiencies. This difference can be partially predicted by sgRNA 
sequence features45,53 and chromatin accessibility at the target site94, and can be used in the 
design of more-efficient libraries53. Although it is tempting to infer quantitative phenotypic 
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information from growth-based Cas9-knockout genetic screens (for example, assigning 
fitness measures to gene knockouts), it is important to realize that quantitative differences in 
depletion or enrichment of the sgRNA-encoding constructs might result from differences in 
sgRNA efficiencies that cause earlier or later knockouts.
Achieving high levels of reagent consistency for dCas9-based transcriptional modulation is 
more challenging, as the effect of different sgRNAs will be affected by the relative distance 
to the transcription start site in a manner that might differ between genes. For both 
repression and activation, library design was guided by the unbiased testing of sets of 
sgRNAs48,49. Reassuringly, using a similar RAF inhibition positive selection experiment, 
we observed high levels of consistency between unique activating sgRNAs49.
On-target loss of function and reagent efficacy
Continuous expression of the Cas9 nuclease using low-MOI lentiviral transduction can 
result in near-complete allelic modification owing to the irreversibility of the genomic 
modification44,46,47, as long as no transgene silencing occurs. However, error-prone DSB 
repair will result in different mutations in different cells, and there is no guarantee that every 
mutation will abolish gene function. For example, small in-frame indels might not disrupt 
gene function. Given that every cell usually has more than one gene copy, this will result in 
a multimodal distribution that consists of defined null, hetero-zygote and wild-type 
expression states (FIG. 4a). This is in contrast to RNAi and dCas9 reagents that modulate 
transcription, which are expected to have similar effects across transduced cells, resulting in 
a general shift in the continuous expression distribution (FIG. 4b). This difference will not 
be apparent from mean expression measurements in bulk cell populations. It is worth noting 
that, in practice, we and others have observed an almost complete level of gene knockout at 
the protein level44,46 for a limited set of tested proteins. This can be explained by additional 
repressive effects of Cas9 binding by steric hindrance, large in-frame deletions that still 
abolish gene function or a higher sensitivity to mutations at these loci. Interestingly, the 
distribution of indel sizes can vary between targeted loci44–46,95,96 and can be partially 
predicted by the DSB flanking sequences95, suggesting that modifications at different loci 
will result in different percentages of disruptive mutations and that such information can be 
incorporated in future libraries to achieve higher knockout efficacy.
Direct comparison of the phenotypes following Cas9 versus shRNA targeting demonstrated 
stronger effects of Cas9 in a few tested cases. This was shown both in pooled formats for 
dCas9-mediated transcriptional repression48 and in arrayed validation44,46 for the Cas9 
nuclease. This suggests a greater efficacy of individual sgRNAs than shRNA in these cases. 
An advantage of using Cas9 nuclease over transcriptional modulation approaches is that 
mutations are irreversible and are not affected by subsequent transgene silencing. However, 
in RNAi, it is easier to monitor and isolate cells that harbour the intended expression 
perturbation. This can be achieved by co-delivery of the RNAi reagent and a reporter but, 
when using Cas9, sgRNA expression does not indicate the duration and magnitude of the 
actual genetic perturbation.
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Off-target activity
Characterizing off-target effects and enhancing the specificity of both Cas9 and RNAi 
reagents continue to be major challenges for improving both research and clinical 
applications.
For Cas9-mediated genome editing, early reports demonstrated that Cas9 tolerates 
mismatches between the sgRNA and the target sequence across the whole recognition site in 
a manner that depends on the mismatch positions, number of mismatches and nucleotide 
identity73,89,97–99. In our design of genome-wide libraries, we used early empirical 
mismatch data89 to choose sgRNAs with minimal predicted off-target activity100. Much 
work is still required in order to fully characterize Cas9 off-target effects. For example, 
recent work has suggested that small insertions or deletions (‘bulges’ in the sgRNA or DNA 
target) can also be tolerated99.
Unbiased methods to detect Cas9-induced DSBs and Cas9-binding events are providing a 
more refined picture of where Cas9 binds and induces unintended modifications. Initial 
attempts to map off-target genome modifications using whole-genome sequencing revealed 
a low incidence of off-target modifications101,102. However, this approach is limited by 
sequencing coverage to detect low-frequency events. Recently, unbiased detection of 
DSBs103,104 revealed unexpected off-target activity that could not have been predicted using 
the current computational tools. Additional experiments using such unbiased methods will 
provide a better understanding of Cas9 target specificity. Another unbiased approach is 
mapping of dCas9 binding using chromatin immunoprecipitation followed by NGS (ChIP–
seq)94,105. Such studies revealed a surprisingly large number of off-target binding events 
mediated by short PAM-proximal homology between the guide RNA and target sequence. 
Reassuringly, when this off-target binding occurs for catalytically active Cas9 it is not 
typically sufficient to induce DSBs, probably because the transient binding and imperfect 
matching of sgRNA to the target sequence is insufficient for DNA cleavage106. This raises 
concern that transcriptional modulation screens might be affected by this high incidence of 
transient off-target binding. However, dCas9-mediated transcriptional repression was shown 
to be sensitive to even a few mismatches48, and genome-wide expression profiling exhibited 
specific effects for both activation and repression48,66. Moreover, large control sets of 
sgRNAs did not show any phenotypic off-target effects for both activation and repression of 
transcription48. For future library designs, specificity could be further improved using 
sgRNA modifications107,108, double-nicking approaches73,109, synthetic Cas9 protein design 
with improved specificity75,110 and the use of different Cas9 orthologues111,112.
For RNAi-based screening strategies, the characterization and avoidance of off-target effects 
have been subject to extensive investigation in recent years33,35,113,114. Early gene 
expression profiling studies revealed that unique siRNA reagents targeting the same genes 
displayed siRNA sequence-driven effects rather than signatures of target gene modulation, 
hinting at low target specificity35. This was later realized to occur as processed siRNAs 
enter the natural miRNA pathways that target transcripts with 3′ untranslated region (3′ 
UTR) sequences that have complementarity to the 5′ region of the siRNA34. Targeting can 
occur even when only eight nucleotides of the siRNA match, an effect that is similar to the 
‘seed region’ in miRNA targeting. Recently, seed effects alone were used to identify host 
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factors that are required for the infection of human cells by various different pathogens115. 
Although these reports were based on the transfection of large amounts of synthetic siRNA, 
gene silencing using different RNAi reagents, such as low-MOI transductions of shRNA or 
shRNAmir, would not necessarily be prone to the same level of off-target effects. Ongoing 
efforts to design algorithms for the more accurate prediction of targets of both endogenous 
miRNAs and exogenous RNAi triggers can improve both the design of RNAi reagent 
libraries and data analysis116. Finally, advances in the mechanistic understanding of miRNA 
biogenesis117,118 can facilitate improved design of RNAi reagents and expression vectors 
that will avoid imprecise Dicer processing and produce higher levels of functional siRNAs.
To summarize, although off-target effects are a major concern for both Cas9 and RNAi 
approaches, they depend on the exact experimental settings and can be minimized by better 
mechanistic understanding and refinement of the currently used tools. Off-target effects are 
a major concern in clinical applications: when attempting to correct a disease-associated 
gene in a patient, a rare off-target mutation could potentially be toxic or oncogenic. By 
contrast, in genetic screens, false-positive hits owing to off-target perturbations can be easily 
avoided by requiring that multiple distinct reagents targeting the same genetic element 
display the same phenotype.
Practical considerations
Many of the technical details for conducting a genome-scale screen using Cas9 are similar to 
RNAi screens. These have been extensively discussed in other reviews3,26,30,55; thus, we 
focus here on topics that are specific to the use of Cas9.
Cas9 delivery
The most commonly used Cas9 protein, from the bacterium S. pyogenes, is a large protein 
that is encoded by a 4.1-kb coding sequence. This suggests two delivery approaches for 
Cas9-mediated genetic screens. The first involves the delivery of only Cas9 (viral 
integration or knock-ins) to generate a stable Cas9-expressing, clonal or polyclonal cell line, 
followed by cell expansion and the delivery of an sgRNA-only library. Clonal cell lines have 
the advantage that a line with high Cas9 expression levels can first be selected. However, 
generating a clonal cell line is not necessarily possible for all cell lines, and cells can 
accumulate mutations during expansion from a single cell. The second approach comprises 
simultaneous delivery of both Cas9 and sgRNAs using library vectors that encode both 
components. Although the first approach can be easily applied in immortalized cell lines, it 
is less feasible in primary cells that are not easily expanded in culture. For the second 
approach, delivery of both Cas9 and sgRNA in a single virus is challenging because viral 
titres can be low owing to the size of the cas9 gene. We have recently improved the titre of 
the single virus system100, thus enabling easier screening applications in primary cells or 
cells that are difficult to transduce. An additional option is to use a cas9-transgenic 
mouse119, which circumvents the need for Cas9 delivery for in vivo or mouse-derived 
primary-cell screening applications.
Adeno-associated virus (AAV) vectors have advantages for in vivo and gene therapy 
applications, as they do not integrate into the genome and are thus less likely to induce 
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oncogenesis. For pooled screening applications, the non-integrating nature of AAV vectors 
is less favourable because genomic integration is used to read out the abundance of the 
different perturbation reagents in a heterogeneous population of selected cells. However, 
AAV-based pooled screens might have advantages in certain in vivo applications: for non-
dividing cells, the viral episome can be used for NGS readout. As the combined size of S. 
pyogenes Cas9 and the sgRNA cassette is already near the packaging limit of AAV, efficient 
in vivo editing by Cas9 AAV delivery requires either the delivery of two separate AAV 
vectors120 or a single vector system using a smaller Cas9 orthologue from the bacterium 
Staphylococcus aureus, which we have recently adapted for in vivo genome editing111.
Culture time before selection for efficient targeting
Success of Cas9 nuclease knockout screens requires a high genomic modification rate with a 
culture time that will suffice to deplete most of the proteins. Measurements of allelic 
modification rates in the first published screens demonstrated close to complete allelic 
modification after approximately 10 days across several gene targets44–47. There is no 
guarantee that all cell lines will display similar results, and it is important to measure allelic 
modification rates as a function of time across several genomic loci before using a cell line 
for screening.
Additional time needs to be added for the depletion of perturbed proteins. In contrast to 
RNAi that acts directly on the mRNA by actively degrading it, both Cas9 nuclease and 
dCas9-mediated protein depletion modulate transcription in the nucleus. This is combined 
with endogenous mRNA degradation and dilution owing to cell proliferation, and results in 
a slower change in mRNA levels (FIG. 1). This difference might be small in rapidly dividing 
cells, but depleting stable proteins in post-mitotic or even slowly dividing cells can require 
longer culture times post-transduction. The mode of delivery can also have an effect on the 
required time for gene perturbation. For example, arrayed format transfection of synthetic 
siRNA libraries121 results in faster knockdown than lentiviral transduction, which requires 
subsequent transgene expression and nucleolytic processing to generate mature siRNAs.
Interaction with cellular machinery
The dependence on endogenous cellular pathways can introduce limitations when designing 
a perturbation screen. RNAi-based tools depend on an active endogenous RNAi pathway, 
whereas Cas9 tools act by exogenous delivery of all components (with the exception of 
endogenous NHEJ mechanisms, which are required for indel formation in knockout screens 
but which are not needed thereafter). The RNAi pathway has been associated with a wide 
variety of cellular processes ranging from host–pathogen interactions and cellular 
differentiation, to cancer122. Additionally, genes that are directly involved in RNAi activity 
cannot be continuously targeted efficiently using synthetic RNAi reagents; therefore, they 
may be missed if they are involved in the screened phenotypes. dCas9-mediated 
transcriptional repression screens can serve as a good alternative for knockdown screens in 
these cases, as this type of silencing is expected to use fewer endogenous pathways (FIG. 2), 
thus reducing the chance of having disruptive interactions between the targeted genetic 
element and the targeting tool.
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An additional concern is the global effect of the targeting reagents on cellular physiology. 
The delivery of large amounts of exogenous siRNAs might saturate the endogenous RNAi 
system, resulting in additional toxic effects33. Although this is a major concern in arrayed 
siRNA transfection experiments, it might be less relevant to low-MOI viral-based shRNA or 
shRNAmir delivery. Cas9 expression in cells, and the external induction of DSBs, has not 
been studied in depth, and more work is still needed to establish that there are no disruptive 
or toxic effects.
Challenges and future outlook
Initial Cas9-mediated screens displayed remarkable results, with high levels of guide 
consistency, genomic modification, hit confirmation and strong phenotypic effects44–49. 
Despite these promising results, there are many aspects of using Cas9 for functional 
genomics that require further study. These include investigation into the cellular response to 
Cas9 delivery and activity in cells, and the demonstration of the same high levels of sgRNA 
consistency across a wider range of cell models and phenotypes. There is also a need for the 
unbiased estimation of false-negative rates, as it is not clear how many of the sgRNA 
reagents in a particular computationally designed library actually perturb the intended 
targets. Although the high consistency of hit sgRNAs per gene suggests that this percentage 
is quite high, there is still a need for an unbiased test across multiple genomic locations. In 
addition, negative selection screens for growth phenotypes remain a challenge, which might 
be addressed by improving the efficiency of sgRNAs53, developing more-sensitive screen 
readout methods and improving the statistical analysis tools.
Knockout, knockdown and activation screens are complementary methods (TABLE 2) that 
together will contribute to a more complete understanding of biological systems. For 
example, genes that retain function at low expression levels will be unlikely to display an 
obvious phenotype upon knockdown and might therefore be missed in knockdown screens. 
By contrast, genes that are essential for cell viability cannot be assessed for their 
contribution to additional cellular phenotypes using complete knockout; partial knockdown 
will be useful in these cases. In addition, as gene regulatory networks are highly inter 
connected and contain multiple feedback loops, the cellular phenotype in response to 
knockout and knockdown can be markedly different.
Screening opportunities using Cas9 extend beyond coding genes. Custom-designed sgRNA 
libraries can be used for the unbiased discovery of regulatory sequences by tiling sgRNAs 
throughout a non-coding genomic region. The delivery of multiple sgRNAs42,72,123 can 
facilitate screening for epistatic effects between pairs of genes124 or can be used to induce 
more-disruptive genetic modifications such as microdeletions. It is also possible to study the 
effects of perturbing non-coding RNAs. In this case, nuclease-induced DSBs might be 
suboptimal, as translational frameshift and NMD are less relevant. Instead, deletion 
approaches using two sgRNAs, or effective dCas9-mediated transcriptional repression, 
might be more suitable. In addition, fusing Cas9 to additional effector domains can facilitate 
high-throughput screens for phenotypic effects of additional epigenetic modifications68. 
Another type of high-throughput assay used Cas9 combined with HDR to conduct saturation 
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mutagenesis experiments within an endogenous locus, thus expanding the possibilities of 
studying sequence-encoded regulatory information125.
NGS has revolutionized our ability to read information from the genome, including the 
DNA sequence itself, the state of the transcriptome and the epi-genome126,127. With these 
new insights into the genome, there is a need to understand the function of genetic elements 
through perturbation. Cas9-mediated screens will have an important role in drawing causal 
links between genetic architecture and phenotypes, and will enhance our ability to decipher 
cellular function in health and disease.
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Glossary
Small 
interfering 
RNA
(siRNA). RNA molecules that are 21–23 nucleotides long and that are 
processed from long double-stranded RNAs;. they are functional 
components of the RNA-induced silencing complex (RISC). siRNAs 
typically target and silence mRNAs by binding perfectly complementary 
sequences in the mRNA and causing their degradation and/or 
translational inhibition.
Short hairpin 
RNA
(shRNA). Small RNAs forming hairpins that can induce sequence-
specific silencing in mammalian cells through RNA interference, both 
when expressed endogenously and when produced exogenously and 
transfected into the cell.
microRNA (miRNA). Small RNA molecules processed from hairpin-containing 
RNA precursors that are produced from endogenous miRNA-encoding 
genes. mi RNAs are 21–23 nucleotides in length and, through the RNA-
induced silencing complex (RISC), they target and silence mRNAs 
containing imperfectly complementary sequences.
Indel (Insertion and deletion). Mutations due to small insertions or deletions of 
DNA sequences.
Single guide 
RNA
(sgRNA). An artificial fusion of CRISPR (clustered regularly 
interspaced short palindromic repeat) RNA (crRNA) and transactivating 
crRNA (tracrRNA) with critical secondary structures for loading onto 
Cas9 for genome editing. It functionally substitutes the complex of 
crRNA and tracrRNA that occurs in natural CRISPR systems. It uses 
RNA–DNA hybridization to guide Cas9 to the genomic target.
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Nonsense-
mediated 
decay
(NMD). An mRNA surveillance mechanism that degrades mRNAs 
containing nonsense mutations to prevent the expression of truncated or 
erroneous proteins.
CRISPRi An engineered transcriptional silencing complex based on catalytically 
inactive Cas9 (dCas9) fusions and/or single guide RNA (sgRNA) 
modification.
CRISPRa An engineered transcriptional activation complex based on catalytically 
inactive Cas9 (dCas9) fusions and/or single guide RNA (sgRNA) 
modification.
False-positive Pertaining to screening results: in a screen that results in a set of putative 
gene hits associated with a phenotype, a false positive is a gene that is 
predicted to be associated but that is actually not associated with the 
phenotype.
False-
negative
Pertaining to screening results: in a screen that results in a set of putative 
gene hits associated with a phenotype, a false negative is a true hit that 
was missed.
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Figure 1. Molecular mechanisms underlying gene perturbation via lentiviral delivery of RNA 
interference reagents, Cas9 nuclease and dCas9 transcriptional effectors
a | Lentiviral transduction begins with the fusion of virus particles with the cell membrane 
and the insertion of the single-stranded RNA (ssRNA) viral genome into the cell cytoplasm. 
A reverse transcriptase then converts the ssRNA genome into double-stranded DNA 
(dsDNA) that is imported into the nucleus and integrates into the host cell genome. Short 
hairpin RNA (shRNA) or single guide RNA (sgRNA) transgenes are then expressed from an 
RNA polymerase III (Pol III) or Pol II promoter. b | For shRNA transgenes, maturation 
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involves a series of nucleolytic processing steps that result in cytoplasmic small interfering 
RNA (siRNA) with sequence complementarity to the target mRNA. Drosha processing is 
required for reagents consisting of shRNAs embedded in microRNA precursors 
(shRNAmirs) but is usually bypassed for simple stem–loop shRNA reagents. Gene silencing 
is achieved by siRNA recruitment to the RNA-induced silencing complex (RISC) for 
mRNA degradation and translational inhibition. c,d | By contrast, both the Cas9 nuclease 
and catalytically inactive Cas9 (dCas9)-mediated transcriptional modulation act in the 
nucleus. The transgene-encoded Cas9–sgRNA complex targets a genomic locus through 
sequence complementarity to the 20-bp sgRNA spacer sequence (part c). For Cas9 nuclease-
mediated knockout, double-strand break (DSB) formation is followed by non-homologous 
end-joining (NHEJ) DNA repair that can introduce an indel mutation and a coding 
frameshift. For dCas9-mediated transcriptional modulation, the modification of expression 
(white arrows) depends on the exact type of fusion of either dCas9 or sgRNA (part d) (FIG. 
2). These induced nuclear events, together with endogenous transcript degradation and 
dilution through cell division, will result in a new steady-state expression level in the 
cytoplasm.
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Figure 2. dCas9-mediated transcriptional modulation
The different ways in which catalytically inactive Cas9 (dCas9) fusions have been used to 
synthetically repress (CRISPRi) or activate (CRISPRa) expression are shown. All 
approaches use a single guide RNA (sgRNA) to direct dCas9 to a chosen genomic location. 
A | To achieve transcriptional repression, dCas9 can be used by itself (whereby it represses 
transcription through steric hindrance)64–68 (part Aa) or can be used as part of a dCas9–
KRAB transcriptional repressor fusion protein48,66 (part Ab). B | For transcriptional 
activation, various approaches have been implemented that involve the VP64 transcriptional 
activator. One approach is a dCas9–VP64 fusion protein68,70–73 (part Ba). In an alternative 
method aimed at signal amplification, dCas9 is fused to a repeating array of peptide 
epitopes, which modularly recruit multiple copies of single-chain variable fragment (ScFv) 
antibodies fused to transcriptional activation domain48,74 (part Bb). Another approach is a 
dCas9–VP64 fusion protein together with a modified sgRNA scaffold with an MS2 RNA 
motif loop. This MS2 RNA loop recruits MS2 coat protein (MCP) fused to additional 
activators such as p65 and heat shock factor 1 (HSF1)49 (part Bc). C | Multiplexed 
activation and repression was implemented using an array of modified sgRNAs with 
different RNA recognition motifs (MS2, PP7 or com) and corresponding RNA-binding 
domains (MCP, PCP or Com) fused to different transcriptional effector domains (KRAB or 
VP64)76. TSS, transcriptional start site. Parts Bb and C adapted from REF. 48 and REF. 76, 
respectively, Cell Press; part Bc adapted from REF. 49, Nature Publishing Group.
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Figure 3. Screening strategies in either arrayed or pooled formats
Genetic screens follow two general formats that differ in the way in which the targeting 
reagents are constructed and how cell targeting and readout is carried out. a | In arrayed 
screens, reagents are separately synthesized and targeting constructs are arranged in 
multiwell plates. Cell targeting is also conducted in multiwell plates using either transfection 
or viral transduction. Screen readout is based on cell population measurements in individual 
wells. b | In pooled screens, reagents are usually synthesized and constructed as a pool. Viral 
transduction limits transgene copy number (ideally, one perturbation per cell), and viral 
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integration enables readout through PCR and next-generation sequencing. Readout is based 
on the comparison of the abundance of the different genomically integrated transgene 
reagents between samples. MOI, multiplicity of infection; sgRNA, single guide RNA; 
shRNA, short hairpin RNA; siRNA, small interfering RNA.
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Figure 4. Distinct expression distributions for knockdown and knockout of a gene
a | Theoretical target gene expression distribution following knockout mediated by 
lentiviral-delivered Cas9 nuclease is shown. This assumes an 80% level of allelic mutations 
that abolish gene function, combining out-of-frame and large deletions, close to complete 
allele modification rate and diploid cells. Although most cells will have a complete 
knockout in both alleles, some cells will retain at least one copy of a functional allele. b | 
Theoretical target gene expression distribution following catalytically inactive Cas9 
(dCas9)-mediated transcriptional repression or RNA interference (RNAi)-mediated 
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knockdown is shown. All transduced cells experience a similar perturbation that results in a 
shift in the target gene expression distribution.
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